Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 27, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Difluprednate Ophthalmic Emulsion, 0.05%.".
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has received final approval from the US health regulator (USFDA) for its generic eye drop Difluprednate Ophthalmic Emulsion, 0.05%. Difluprednate is a corticosteroid used to treat eye inflammation and pain, typically after eye surgery, and is the generic equivalent of the brand Durezol. With this final approval, Alembic can now commercially launch and sell this product in the US market. This adds another product to Alembic's US generics portfolio, which is a key revenue driver for the company. The approval strengthens the company's presence in the US ophthalmology segment.
Positive for the stock — the approval opens up a new revenue stream from US sales, though the actual financial impact will depend on market share captured and competition in this generic category.